Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study

Jannik Helweg-Larsen; Thomas Benfield; Chiara Atzori; Robert F Miller

doi:10.1093/jac/dkp372

Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study

Jannik Helweg-Larsen, Thomas Benfield, Chiara Atzori, Robert F Miller

94 Citationer (Scopus)

Abstract

First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.

Originalsprog	Engelsk
Tidsskrift	Journal of Antimicrobial Chemotherapy
Vol/bind	64
Udgave nummer	6
Sider (fra-til)	1282-90
Antal sider	9
ISSN	0305-7453
DOI	https://doi.org/10.1093/jac/dkp372
Status	Udgivet - 1 dec. 2009

Adgang til dokumentet

10.1093/jac/dkp372

Citationsformater

@article{1d36be905cc7413a9a83e890eb50513f,

title = "Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study",

abstract = "First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.",

author = "Jannik Helweg-Larsen and Thomas Benfield and Chiara Atzori and Miller, {Robert F}",

year = "2009",

month = dec,

day = "1",

doi = "10.1093/jac/dkp372",

language = "English",

volume = "64",

pages = "1282--90",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study

AU - Helweg-Larsen, Jannik

AU - Benfield, Thomas

AU - Atzori, Chiara

AU - Miller, Robert F

PY - 2009/12/1

Y1 - 2009/12/1

N2 - First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.

AB - First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy.

U2 - 10.1093/jac/dkp372

DO - 10.1093/jac/dkp372

M3 - Journal article

C2 - 19858161

SN - 0305-7453

VL - 64

SP - 1282

EP - 1290

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -

Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater